Silver Book Fact

After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus 15.2%.

Patel J, Chen F, Da Cruz L, Rubin G, et al. Contrast Sensitivity Outcomes in the ABC Trial: A randomized trial of bevacizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. February 2011; 52(6): 3089-93. http://www.iovs.org/content/early/2011/02/09/iovs.10-6208.full.pdf

Reference

Title
Contrast Sensitivity Outcomes in the ABC Trial: A randomized trial of bevacizumab for neovascular age-related macular degeneration
Publication
Invest Ophthalmol Vis Sci
Publication Date
February 2011
Authors
Patel J, Chen F, Da Cruz L, Rubin G, et al.
Volume & Issue
Volume 52, Issue 6
Pages
3089-93
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • Mobile Exam for DR
    Use of a mobile examination for DR screening in Finland decreased visual impairment by 86% in the covered area.  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.  
  • DR Treatment Reduced Risk of Blindness
    Appropriate treatment can reduce the risk of blindness or moderate vision loss from DR by more than 90%.